
    
      The primary objective of this study is to assess the safety and efficacy of TUS using the
      Sonolysis Headframe in combination with systemic tPA (Treatment group) compared to systemic
      tPA alone (Control group) in subjects with acute ischemic stroke.

      Number of Subjects Required:

      Lead-in Phase: 40 subjects in the U.S.; Primary Phase: 556 total enrolled subjects (278 per
      arm)

      Number of Study Centers:

      Lead-in Phase: Up to 20 Institutions in U.S.; Primary Phase: Up to 70 Institutions worldwide
    
  